[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxUjdfsnlbJzyLpup4N67QcgQ-4EhUt9GXE15xpFI6dA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"Groupe Hospitalier Pitie-Salpetriere",[4],63,false,1,3,1995848,33,[13,16,18,20,22,25,27,29],{"name":14,"count":15},"Myocarditis",4,{"name":17,"count":15},"Cancer",{"name":19,"count":9},"Pneumonia",{"name":21,"count":9},"Cardiac Complication",{"name":23,"count":24},"Adverse Drug Event",2,{"name":26,"count":24},"Drug Toxicity",{"name":28,"count":24},"Parkinson's Disease",{"name":30,"count":24},"Diabetes Mellitus, Type 2",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06515678","Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","2024-08-01","arm A - angiotensin converting enzyme inhibitors",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,74,92,110,136,162,188,211,250,293,321,348,373,398,424,450,477,508,534,561,585,611,634,658,684,708,733,761,787,814],{"intervention":36,"totalTrials":8,"cells":46},{"EARLY_PHASE1":47,"PHASE1":50,"PHASE2":52,"PHASE3":54,"PHASE4":56,"NA":58},{"trials":48,"activeCount":49},[],0,{"trials":51,"activeCount":49},[],{"trials":53,"activeCount":49},[],{"trials":55,"activeCount":49},[],{"trials":57,"activeCount":49},[],{"trials":59,"activeCount":8,"soonestReadout":35},[60],{"nctId":33,"briefTitle":34,"status":61,"phases":62,"primaryCompletion":35,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":71},"ACTIVE_NOT_RECRUITING",[],"2024-08-31","2024-05-20",9464,[67,68,69,70],"Ovarian Cancer","Antiangiogenic-Associated Hypertension","Adjuvant Bevacizumab","Hypertension",[36,72,73],"arm B - calcium channel blockers","arm R - angiotensin receptor blockers ARB",{"intervention":72,"totalTrials":8,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":77,"activeCount":49},[],{"trials":79,"activeCount":49},[],{"trials":81,"activeCount":49},[],{"trials":83,"activeCount":49},[],{"trials":85,"activeCount":49},[],{"trials":87,"activeCount":8,"soonestReadout":35},[88],{"nctId":33,"briefTitle":34,"status":61,"phases":89,"primaryCompletion":35,"completion":63,"start":64,"enrollment":65,"conditions":90,"interventions":91},[],[67,68,69,70],[36,72,73],{"intervention":73,"totalTrials":8,"cells":93},{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":104},{"trials":95,"activeCount":49},[],{"trials":97,"activeCount":49},[],{"trials":99,"activeCount":49},[],{"trials":101,"activeCount":49},[],{"trials":103,"activeCount":49},[],{"trials":105,"activeCount":8,"soonestReadout":35},[106],{"nctId":33,"briefTitle":34,"status":61,"phases":107,"primaryCompletion":35,"completion":63,"start":64,"enrollment":65,"conditions":108,"interventions":109},[],[67,68,69,70],[36,72,73],{"intervention":111,"totalTrials":8,"cells":112},"stavudine",{"EARLY_PHASE1":113,"PHASE1":115,"PHASE2":117,"PHASE3":119,"PHASE4":121,"NA":134},{"trials":114,"activeCount":49},[],{"trials":116,"activeCount":49},[],{"trials":118,"activeCount":49},[],{"trials":120,"activeCount":49},[],{"trials":122,"activeCount":49},[123],{"nctId":124,"briefTitle":125,"status":126,"phases":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},"NCT00235222","Evaluation of Viral Efficacy and Safety of a Reduced Dose of Stavudine (d4T): THE PHOENIX STUDY","UNKNOWN",[42],"2006-03","2004-06",57,[132],"HIV",[111],{"trials":135,"activeCount":49},[],{"intervention":137,"totalTrials":8,"cells":138},"prednisone discontinuation",{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":158,"NA":160},{"trials":140,"activeCount":49},[],{"trials":142,"activeCount":49},[],{"trials":144,"activeCount":49},[],{"trials":146,"activeCount":49},[147],{"nctId":148,"briefTitle":149,"status":126,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT02558517","Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus",[41],"2017-01","2018-01","2014-01",136,[156],"Systemic Lupus Erythematosus",[137],{"trials":159,"activeCount":49},[],{"trials":161,"activeCount":49},[],{"intervention":163,"totalTrials":8,"cells":164},"ceftazidime and amikacin",{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":182,"PHASE4":184,"NA":186},{"trials":166,"activeCount":49},[],{"trials":168,"activeCount":49},[],{"trials":170,"activeCount":49},[171],{"nctId":172,"briefTitle":173,"status":174,"phases":175,"primaryCompletion":176,"completion":177,"start":178,"enrollment":179,"conditions":180,"interventions":181},"NCT00786305","Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia","COMPLETED",[40],"2008-09","2008-11","2004-10",40,[19],[163,163],{"trials":183,"activeCount":49},[],{"trials":185,"activeCount":49},[],{"trials":187,"activeCount":49},[],{"intervention":189,"totalTrials":8,"cells":190},"donepezil",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":205,"PHASE4":207,"NA":209},{"trials":192,"activeCount":49},[],{"trials":194,"activeCount":49},[],{"trials":196,"activeCount":49},[197],{"nctId":198,"briefTitle":199,"status":126,"phases":200,"enrollment":201,"conditions":202,"interventions":204},"NCT00139373","Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy",[40],16,[203],"Supranuclear Palsy, Progressive",[189],{"trials":206,"activeCount":49},[],{"trials":208,"activeCount":49},[],{"trials":210,"activeCount":49},[],{"intervention":212,"totalTrials":24,"cells":213},"ICI",{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":224},{"trials":215,"activeCount":49},[],{"trials":217,"activeCount":49},[],{"trials":219,"activeCount":49},[],{"trials":221,"activeCount":49},[],{"trials":223,"activeCount":49},[],{"trials":225,"activeCount":49},[226,236],{"nctId":227,"briefTitle":228,"status":174,"phases":229,"primaryCompletion":230,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":235},"NCT03387540","Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions",[],"2017-12-04","2017-12-31","2017-12-02",104,[14,21],[212],{"nctId":237,"briefTitle":238,"status":126,"phases":239,"primaryCompletion":240,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":249},"NCT04294771","JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors",[],"2025-01-01","2019-01-01",500000,[14,244,245,246,247,248],"Cardiomyopathies","Heart Diseases","Cardiovascular Diseases","Pericarditis","Vasculitis",[212],{"intervention":251,"totalTrials":24,"cells":252},"Immune checkpoint inhibitor",{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":254,"activeCount":49},[],{"trials":256,"activeCount":49},[],{"trials":258,"activeCount":49},[],{"trials":260,"activeCount":49},[],{"trials":262,"activeCount":49},[],{"trials":264,"activeCount":49},[265,281],{"nctId":266,"briefTitle":267,"status":174,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":280},"NCT03492242","Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction",[],"2018-09-30","2018-02-01",1000,[273,17,274,275,276,277,278,279],"Arthritis","Cardiac Disease","Endocrine System Diseases","Autoimmune Diseases","Ophthalmopathy","Myositis","Neuropathy",[251],{"nctId":282,"briefTitle":283,"status":174,"phases":284,"primaryCompletion":285,"completion":286,"start":287,"enrollment":288,"conditions":289,"interventions":292},"NCT05934214","EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Database",[],"2023-12-31","2024-02-29","2023-01-01",141630,[17,290,291],"Immune-related Adverse Event","Immune Checkpoint Inhibitor-Related Myocarditis",[251],{"intervention":294,"totalTrials":8,"cells":295},"Drugs inducing uveitis",{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":302,"PHASE4":304,"NA":306},{"trials":297,"activeCount":49},[],{"trials":299,"activeCount":49},[],{"trials":301,"activeCount":49},[],{"trials":303,"activeCount":49},[],{"trials":305,"activeCount":49},[],{"trials":307,"activeCount":49},[308],{"nctId":309,"briefTitle":310,"status":174,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":271,"conditions":315,"interventions":320},"NCT03899922","Monitoring Drug-induced Uveitis",[],"2020-04-01","2023-04-04","2019-04-01",[316,317,318,319],"Uveitis","Uveitis Drug-Induced","Eye Diseases","Uvea--Diseases",[294],{"intervention":322,"totalTrials":8,"cells":323},"Drug inducing antiphospholipid syndrome",{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":325,"activeCount":49},[],{"trials":327,"activeCount":49},[],{"trials":329,"activeCount":49},[],{"trials":331,"activeCount":49},[],{"trials":333,"activeCount":49},[],{"trials":335,"activeCount":49},[336],{"nctId":337,"briefTitle":338,"status":174,"phases":339,"primaryCompletion":340,"completion":341,"start":342,"enrollment":343,"conditions":344,"interventions":347},"NCT03994302","Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)",[],"2021-06-30","2023-04-08","2019-06-01",2700,[345,346,23,26],"Antiphospholipid Syndrome","Immune Disease",[322],{"intervention":349,"totalTrials":8,"cells":350},"Drugs inducing hyperammonemia",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":352,"activeCount":49},[],{"trials":354,"activeCount":49},[],{"trials":356,"activeCount":49},[],{"trials":358,"activeCount":49},[],{"trials":360,"activeCount":49},[],{"trials":362,"activeCount":49},[363],{"nctId":364,"briefTitle":365,"status":174,"phases":366,"primaryCompletion":367,"completion":313,"start":368,"enrollment":343,"conditions":369,"interventions":372},"NCT03947034","Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)",[],"2020-05-30","2019-05-01",[370,371,23,26],"Hyperammonemia","Metabolic Disease",[349],{"intervention":374,"totalTrials":8,"cells":375},"drug inducing hematological toxicity",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":382,"PHASE4":384,"NA":386},{"trials":377,"activeCount":49},[],{"trials":379,"activeCount":49},[],{"trials":381,"activeCount":49},[],{"trials":383,"activeCount":49},[],{"trials":385,"activeCount":49},[],{"trials":387,"activeCount":49},[388],{"nctId":389,"briefTitle":390,"status":174,"phases":391,"primaryCompletion":392,"completion":341,"start":393,"enrollment":271,"conditions":394,"interventions":397},"NCT03828942","Monitoring the HeMAtological TOXicity of Drugs (HeMATOX)",[],"2022-02-01","2019-02-01",[395,396],"Hematological Abnormality","Hematotoxicity",[374],{"intervention":399,"totalTrials":8,"cells":400},"phenome-wide association study",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":402,"activeCount":49},[],{"trials":404,"activeCount":49},[],{"trials":406,"activeCount":49},[],{"trials":408,"activeCount":49},[],{"trials":410,"activeCount":49},[],{"trials":412,"activeCount":49},[413],{"nctId":414,"briefTitle":415,"status":174,"phases":416,"primaryCompletion":417,"completion":417,"start":418,"enrollment":419,"conditions":420,"interventions":423},"NCT03597659","PheWAS of a Polygenic Predictor of Thyroid Function",[],"2018-07-01","2017-09-01",37154,[421,422],"Thyroid","Genetic Predisposition to Disease",[399],{"intervention":425,"totalTrials":8,"cells":426},"Dalteparin",{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":437},{"trials":428,"activeCount":49},[],{"trials":430,"activeCount":49},[],{"trials":432,"activeCount":49},[],{"trials":434,"activeCount":49},[],{"trials":436,"activeCount":49},[],{"trials":438,"activeCount":49},[439],{"nctId":440,"briefTitle":441,"status":174,"phases":442,"primaryCompletion":443,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},"NCT03218514","Venous Thromboprophylaxis in Bariatric Surgery",[],"2017-03","2017-07","2014-07",118,[448],"Obesity",[425],{"intervention":451,"totalTrials":8,"cells":452},"Drugs inducing hepatological toxicity",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":454,"activeCount":49},[],{"trials":456,"activeCount":49},[],{"trials":458,"activeCount":49},[],{"trials":460,"activeCount":49},[],{"trials":462,"activeCount":49},[],{"trials":464,"activeCount":49},[465],{"nctId":466,"briefTitle":467,"status":174,"phases":468,"primaryCompletion":469,"completion":313,"start":470,"enrollment":271,"conditions":471,"interventions":476},"NCT03833297","Monitoring the HePAtological TOXicity of Drugs (HePATOX)",[],"2020-02-04","2019-02-04",[472,473,474,475],"Liver Diseases","Liver Dysfunction","Liver Failure","Hepatotoxicity",[451],{"intervention":478,"totalTrials":8,"cells":479},"Anti-Cancer Agents",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":490},{"trials":481,"activeCount":49},[],{"trials":483,"activeCount":49},[],{"trials":485,"activeCount":49},[],{"trials":487,"activeCount":49},[],{"trials":489,"activeCount":49},[],{"trials":491,"activeCount":49},[492],{"nctId":493,"briefTitle":494,"status":126,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":507},"NCT03882580","Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care",[],"2025-03-01","2019-03-01",5000,[500,501,21,502,503,504,505,506],"Cardiovascular Complication","Cardiovascular Insufficiency","Oncologic Complications","Cardiac Insufficiency","Metabolic Disorder","Vascular Disorder","Cardiac Disorder",[478],{"intervention":509,"totalTrials":8,"cells":510},"Any drug used to treat Covid-19",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":521},{"trials":512,"activeCount":49},[],{"trials":514,"activeCount":49},[],{"trials":516,"activeCount":49},[],{"trials":518,"activeCount":49},[],{"trials":520,"activeCount":49},[],{"trials":522,"activeCount":49},[523],{"nctId":524,"briefTitle":525,"status":174,"phases":526,"primaryCompletion":287,"completion":287,"start":527,"enrollment":271,"conditions":528,"interventions":533},"NCT04314817","Adverse Events Related to Treatments Used Against Coronavirus Disease 2019",[],"2020-03-17",[529,530,531,532],"Coronavirus","Iatrogenic Disease","Acute Kidney Injury","ARDS, Human",[509],{"intervention":535,"totalTrials":8,"cells":536},"blood samples",{"EARLY_PHASE1":537,"PHASE1":539,"PHASE2":541,"PHASE3":543,"PHASE4":545,"NA":547},{"trials":538,"activeCount":49},[],{"trials":540,"activeCount":49},[],{"trials":542,"activeCount":49},[],{"trials":544,"activeCount":49},[],{"trials":546,"activeCount":49},[],{"trials":548,"activeCount":49},[549],{"nctId":550,"briefTitle":551,"status":174,"phases":552,"primaryCompletion":553,"completion":553,"start":554,"enrollment":555,"conditions":556,"interventions":560},"NCT03782129","Five-year Mortality Rate in People With Diabetic Foot Ulcer",[],"2018-12","2009-03",347,[557,558,559],"Diabetes Mellitus","Diabetic Foot","Diabetes Complications",[535],{"intervention":562,"totalTrials":8,"cells":563},"Hormonal therapies: G03, H01C and L02 in the ATC classification",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":565,"activeCount":49},[],{"trials":567,"activeCount":49},[],{"trials":569,"activeCount":49},[],{"trials":571,"activeCount":49},[],{"trials":573,"activeCount":49},[],{"trials":575,"activeCount":49},[576],{"nctId":577,"briefTitle":578,"status":174,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":584},"NCT03193138","CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)",[],"2017-06-21","2017-06-07",3096,[245],[562],{"intervention":586,"totalTrials":8,"cells":587},"Amiodarone",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":596,"NA":598},{"trials":589,"activeCount":49},[],{"trials":591,"activeCount":49},[],{"trials":593,"activeCount":49},[],{"trials":595,"activeCount":49},[],{"trials":597,"activeCount":49},[],{"trials":599,"activeCount":49},[600],{"nctId":601,"briefTitle":602,"status":174,"phases":603,"primaryCompletion":604,"completion":604,"start":605,"enrollment":606,"conditions":607,"interventions":610},"NCT03413150","Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias",[],"2012-04","2007-01",80,[608,609],"Atrial Fibrillation","Atrial Tachycardia",[586],{"intervention":612,"totalTrials":8,"cells":613},"Antineoplastic and Immunomodulating Agents",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":615,"activeCount":49},[],{"trials":617,"activeCount":49},[],{"trials":619,"activeCount":49},[],{"trials":621,"activeCount":49},[],{"trials":623,"activeCount":49},[],{"trials":625,"activeCount":49},[626],{"nctId":627,"briefTitle":628,"status":174,"phases":629,"primaryCompletion":630,"completion":341,"start":631,"enrollment":242,"conditions":632,"interventions":633},"NCT03530215","Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)",[],"2022-05-01","2018-05-02",[274,17],[612],{"intervention":635,"totalTrials":8,"cells":636},"Enzalutamide",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":638,"activeCount":49},[],{"trials":640,"activeCount":49},[],{"trials":642,"activeCount":49},[],{"trials":644,"activeCount":49},[],{"trials":646,"activeCount":49},[],{"trials":648,"activeCount":49},[649],{"nctId":650,"briefTitle":651,"status":174,"phases":652,"primaryCompletion":287,"completion":341,"start":241,"enrollment":242,"conditions":653,"interventions":657},"NCT04290611","a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY",[],[654,279,655,656],"Prostate Cancer","Epilepsy","Encephalopathy",[635],{"intervention":659,"totalTrials":8,"cells":660},"Cardiac complication induced by VEGF\u002FVEGFR inhibitor",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":662,"activeCount":49},[],{"trials":664,"activeCount":49},[],{"trials":666,"activeCount":49},[],{"trials":668,"activeCount":49},[],{"trials":670,"activeCount":49},[],{"trials":672,"activeCount":49},[673],{"nctId":674,"briefTitle":675,"status":174,"phases":676,"primaryCompletion":677,"completion":678,"start":679,"enrollment":680,"conditions":681,"interventions":683},"NCT03413176","Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.",[],"2018-01-15","2018-01-31","2018-01-01",150000,[21,682],"Vascular Diseases",[659],{"intervention":685,"totalTrials":8,"cells":686},"Kinase inhibitor",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":695,"NA":697},{"trials":688,"activeCount":49},[],{"trials":690,"activeCount":49},[],{"trials":692,"activeCount":49},[],{"trials":694,"activeCount":49},[],{"trials":696,"activeCount":49},[],{"trials":698,"activeCount":49},[699],{"nctId":700,"briefTitle":701,"status":174,"phases":702,"primaryCompletion":497,"completion":497,"start":703,"enrollment":704,"conditions":705,"interventions":707},"NCT03896139","Identification of PAthways of Kinase Inhibitors TOxicity",[],"2017-01-01",4000,[706],"Kinase Inhibitors Toxicity",[685],{"intervention":709,"totalTrials":8,"cells":710},"Hormonal therapies L02 in the ATC classification",{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":712,"activeCount":49},[],{"trials":714,"activeCount":49},[],{"trials":716,"activeCount":49},[],{"trials":718,"activeCount":49},[],{"trials":720,"activeCount":49},[],{"trials":722,"activeCount":49},[723],{"nctId":724,"briefTitle":725,"status":174,"phases":726,"primaryCompletion":727,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},"NCT03259711","Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase",[],"2017-08-14","2001-01",20000,[731],"Cardiac Affections",[709],{"intervention":734,"totalTrials":8,"cells":735},"L02",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":744,"NA":746},{"trials":737,"activeCount":49},[],{"trials":739,"activeCount":49},[],{"trials":741,"activeCount":49},[],{"trials":743,"activeCount":49},[],{"trials":745,"activeCount":49},[],{"trials":747,"activeCount":49},[748],{"nctId":749,"briefTitle":750,"status":174,"phases":751,"primaryCompletion":752,"completion":752,"start":753,"enrollment":754,"conditions":755,"interventions":760},"NCT03243604","cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study",[],"2017-07-13","2017-05-16",1717,[756,757,758,759],"Arrhythmias, Cardiac","Atrial Fibrillation and Flutter","Tachycardia, Supraventricular","Cardiac Failure",[734],{"intervention":762,"totalTrials":8,"cells":763},"Drug inducing myocarditis",{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":765,"activeCount":49},[],{"trials":767,"activeCount":49},[],{"trials":769,"activeCount":49},[],{"trials":771,"activeCount":49},[],{"trials":773,"activeCount":49},[],{"trials":775,"activeCount":49},[776],{"nctId":777,"briefTitle":778,"status":174,"phases":779,"primaryCompletion":780,"completion":313,"start":781,"enrollment":782,"conditions":783,"interventions":786},"NCT03855982","Monitoring Drug-induced Myocarditis (CardiTOX)",[],"2020-02-25","2019-04-09",6000,[14,784,785],"Myocardial Failure","Myocardial Dysfunction",[762],{"intervention":788,"totalTrials":8,"cells":789},"drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":791,"activeCount":49},[],{"trials":793,"activeCount":49},[],{"trials":795,"activeCount":49},[],{"trials":797,"activeCount":49},[],{"trials":799,"activeCount":49},[],{"trials":801,"activeCount":49},[802],{"nctId":803,"briefTitle":804,"status":174,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":813},"NCT03480529","Monitoring the IMmUological TOXicity of Drugs",[],"2018-03-10","2018-03-01",662,[273,156,810,811,812],"Rheumatoid Arthritis","Capillary Leak Syndrome","Hepatitis",[788],{"intervention":815,"totalTrials":8,"cells":816},"CAR T-cell and Cellular Therapies",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":827},{"trials":818,"activeCount":49},[],{"trials":820,"activeCount":49},[],{"trials":822,"activeCount":49},[],{"trials":824,"activeCount":49},[],{"trials":826,"activeCount":49},[],{"trials":828,"activeCount":49},[829],{"nctId":830,"briefTitle":831,"status":174,"phases":832,"primaryCompletion":287,"completion":341,"start":241,"enrollment":833,"conditions":834,"interventions":836},"NCT04279470","Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events",[],100000,[835,17],"Adverse Drug Reactions",[815]]